Who
Tyler Zeronda
Director
Company insider
Files Form 4 as: Chief Financial Officer, Yarrow Bioscience.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Jun 2021
- Last trade
- 27 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 29 Jul 2026 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,798 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,798 at $0.00 | filing |
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $20K22,516 at $0.8976 | filing |
| 23 Jul 2026filed 24 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $20K22,516 at $0.90 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,2543,464 at $0.6507 | filing |
| 30 Jun 2026filed 2 Jul 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,2523,464 at $0.65 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,3944,007 at $0.5975 | filing |
| 31 Mar 2026filed 2 Apr 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,4044,007 at $0.60 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,5587,858 at $0.5801 | filing |
| 31 Dec 2025filed 5 Jan 2026 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $4,5587,858 at $0.58 | filing |
| 30 Sep 2025filed 2 Oct 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,1633,420 at $0.34 | filing |
| 30 Jun 2025filed 2 Jul 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $5,6433,420 at $1.65 | filing |
| 31 Mar 2025filed 2 Apr 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $13K8,399 at $1.58 | filing |
| 21 Jan 2025filed 23 Jan 2025 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,000 at $0.00 | filing |
| 31 Dec 2024filed 2 Jan 2025 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K4,675 at $3.35 | filing |
| 30 Sep 2024filed 2 Oct 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $15884 at $1.88 | filing |
| 1 Jul 2024filed 3 Jul 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $17792 at $1.92 | filing |
| 1 Apr 2024filed 3 Apr 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $29094 at $3.08 | filing |
| 2 Jan 2024filed 3 Jan 2024 | VYNE TherapeuticsBiotechnology | SEC FORM 4 Code F | $21293 at $2.28 | filing |
| 1 Jan 2024filed 3 Jan 2024 | VYNE Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.